Reach Us +1-947-333-4405


Belimumab: Present and future

Belimumab, a B lymphocyte stimulator (BLyS) inhibitor, recently approved for patients with active, autoantibody-positive systemic lupus erythematosus (SLE) has paved the way for newer drugs that could arrest the complex autoimmune process and reverse the disease pathology. However, there is a need to further delineate long term effects of belimumab on disease activity and progression in patients with lupus nephritis, pregnancy and paediatric populations. Here, we review the on-going clinical trials and registry studies of belimumab in different populations that could define its role in the SLE armamentarium.


CD Tripathi and Preeta Kaur Chugh

Abstract | Full-Text | PDF

Share this  Facebook  Twitter  LinkedIn  Google+
Flyer image

Abstracted/Indexed in

  • Index Copernicus
  • Google Scholar
  • China National Knowledge Infrastructure (CNKI)
  • Directory of Research Journal Indexing (DRJI)
  • WorldCat
  • Geneva Foundation for Medical Education and Research
  • Secret Search Engine Labs